Hepion Pharmaceuticals, Inc. [HEPA] Stock Forecast

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.

Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 9:45 a.m. ET in NYC.

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution –

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

Hepion Pharmaceuticals' (NASDAQ: HEPA) stock price went parabolic on Monday after the company made an important announcement about its mid-stage trial. The shares jumpd by more than 110% and reached a high of $19.66, the highest level since January 17.

Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is rising higher on Monday as the company prepares to cover clinical trial results. Hepion Pharmaceuticals is holding a conference call at 8:30 a.m.

EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial before the market opens on Monday, May 22, 2023.

EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its Chief Scientific Officer, Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting, which is being held April 15-19, 2023, in Orlando, Florida.

Hepion Pharmaceuticals, Inc. is a US stock , located in Edison of Nj and trading under the symbol HEPA

Hepion Pharmaceuticals, Inc. stock price is $2.14 today.

Yes, Hepion Pharmaceuticals, Inc. is a publicly traded company.